Skip to main content

Table 2 Univariate Analysis of Prognostic factors of BCSS and OS in Metastatic Breast Cancer

From: The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer

Characteristic

BCSS

OS

HR

95%CI

p

HR

95%CI

p

Age

1.017

1.015–1.018

< 0.001

1.024

1.022–1.025

< 0.001

Race

 White

1

  

1

  

 Black

1.081

1.019–1.147

0.009

1.313

1.248–1.381

< 0.001

 Others

0.893

0.813–0.98

0.017

0.91

0.839–0.986

0.022

Marital status

 Married

1

  

1

  

 Unmarried

1.235

1.177–1.297

< 0.001

1.482

1.421–1.545

< 0.001

Grade

 I

1

  

1

  

 II

1.154

1.023–1.303

0.02

1.267

1.148–1.398

< 0.001

 III & IV

1.377

1.223–1.551

< 0.001

1.824

1.656–2.008

< 0.001

BC Subtype

 HR+/HER2-

1

  

1

  

 HR+/HER2+

1.025

0.949–1.108

0.528

0.816

0.763–0.873

< 0.001

 HR−/HER2+

1.312

1.193–1.443

< 0.001

1.115

1.027–1.212

< 0.001

 Triple negative

1.73

1.616–1.852

< 0.001

2.539

2.395–2.691

< 0.001

Stage T

 T0/T1

1

  

1

  

 T2

0.917

0.841–1.001

0.052

1.002

0.935–1.074

0.96

 T3

0.92

0.836–1.012

0.085

1.104

1.021–1.194

0.013

 T4

1.149

1.058–1.248

0.001

1.493

1.397–1.595

< 0.001

Stage N

 N0

1

  

1

  

 N1

0.854

0.8–0.912

< 0.001

0.892

0.845–0.942

< 0.001

 N2

0.728

0.662–0.8

< 0.001

0.845

0.779–0.918

< 0.001

 N3

0.902

0.844–0.965

0.003

1.096

1.036–1.159

0.001

Surgery

 No

1

  

1

  

 Yes

0.622

0.588–0.659

< 0.001

0.513

0.489–0.538

< 0.001

Radiotherapy

 No

1

  

1

  

 Yes

0.754

0.717–0.793

< 0.001

0.756

0.723–0.79

< 0.001

Chemotherapy

 No/Unknown

1

  

1

  

 Yes

0.655

0.625–0.686

< 0.001

0.626

0.601–0.651

< 0.001

Metastatic site

 Bone

1

  

1

  

 Lung

1.319

1.214–1.434

< 0.001

1.435

1.339–1.537

< 0.001

 Liver

1.365

1.242–1.5

< 0.001

1.415

1.306–1.532

< 0.001

 Brain

1.708

1.442–2.023

< 0.001

2.492

2.161–2.874

< 0.001

 Other

1.127

1.021–1.244

< 0.001

1.285

1.187–1.392

< 0.001

 Multiple

1.484

1.405–1.567

< 0.001

1.944

1.855–2.037

< 0.001

  1. Abbreviations: BCSS breast cancer–specific survival, OS overall survival, HR hazard ratio, CI confidence interval, BC breast cancer, HR hormone receptor, HER2 human epidermal growth receptor 2, TN triple negative